The current stock price of LFMDP is 22.77 USD. In the past month the price increased by 0.09%. In the past year, price increased by 0.09%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 28.59 | 36.38B | ||
| DOCS | DOXIMITY INC-CLASS A | 27.86 | 8.60B | ||
| WAY | WAYSTAR HOLDING CORP | 23.72 | 6.08B | ||
| HTFL | HEARTFLOW INC | N/A | 2.59B | ||
| CERT | CERTARA INC | 18.08 | 1.44B | ||
| SDGR | SCHRODINGER INC | N/A | 1.36B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.29B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 644 | 1.09B | ||
| PHR | PHREESIA INC | N/A | 1.03B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 8.09 | 960.59M | ||
| HSTM | HEALTHSTREAM INC | 33.87 | 683.30M | ||
| CTEV | CLARITEV CORP | N/A | 488.13M |
LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The company is headquartered in New York City, New York and currently employs 304 full-time employees. The company went IPO on 2001-07-11. The firm offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The firm owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
LIFEMD INC - LFMD 8 7/8 PERP
236 Fifth Avenue, Suite 400
New York City NEW YORK US
Employees: 306
Phone: 18663515907
LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The company is headquartered in New York City, New York and currently employs 304 full-time employees. The company went IPO on 2001-07-11. The firm offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The firm owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
The current stock price of LFMDP is 22.77 USD. The price decreased by -2.19% in the last trading session.
LIFEMD INC - LFMD 8 7/8 PERP (LFMDP) has a dividend yield of 9.53%. The yearly dividend amount is currently 0.08.
LFMDP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
14 analysts have analysed LFMDP and the average price target is 61.23 USD. This implies a price increase of 168.89% is expected in the next year compared to the current price of 22.77.
LIFEMD INC - LFMD 8 7/8 PERP (LFMDP) operates in the Health Care sector and the Health Care Technology industry.
You can find the ownership structure of LIFEMD INC - LFMD 8 7/8 PERP (LFMDP) on the Ownership tab.
ChartMill assigns a technical rating of 2 / 10 to LFMDP. When comparing the yearly performance of all stocks, LFMDP is a bad performer in the overall market: 69.39% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to LFMDP. LFMDP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months LFMDP reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 78.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.68% | ||
| ROE | -586.53% | ||
| Debt/Equity | 0 |
14 analysts have analysed LFMDP and the average price target is 61.23 USD. This implies a price increase of 168.89% is expected in the next year compared to the current price of 22.77.
For the next year, analysts expect an EPS growth of 61.09% and a revenue growth 15.11% for LFMDP